Piper Sandler initiates coverage of Nektar Therapeutics, citing REZPEG’s Treg-focused action as a potential breakthrough for Alopecia areata treatment.
Latest Ratings for NKTR
DateFirmActionFromTo Mar 2022OppenheimerUpgradesPerformOutperform Nov 2021BenchmarkUpgradesHoldBuy Nov 2021SVB LeerinkMaintainsMarket Perform
View More Analyst Ratings for NKTR
View the Latest Analyst Ratings
read more Read More
